Growth factors for treating diabetic foot ulcers

Martí‐Carvajal, Arturo J; Gluud, Christian; Nicola, Susana; Simancas‐Racines, Daniel; Revéiz, Ludovic; Oliva, Patricio; Cedeño-Taborda, Jorge

doi:10.1002/14651858.cd008548.pub2

Cited by 109 publications

(89 citation statements)

References 151 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Platelet‐derived growth factor (PDGF), vascular endothelial growth factor (VEGF), epidermal growth factor (EGF), fibroblast growth factor (FGF), transforming growth factor‐β (TGF‐β), and insulin‐like growth factor (IGF) have all been applied in the topical management of chronic wounds. [ 67,68 ] However, exogenously administered GFs suffer from rapid degradation within the wound site, leading to only transient therapeutic concentrations of GFs thus reducing their therapeutic efficacy. [ 2 ] To address these challenges, traditional GF delivery formulations require high doses and/or long periods of repeated administration which may lead to serious side effects [ 69 ] as well as high costs.…”

Section: Stimuli‐responsive Growth Factor Delivery Systems In Tissue mentioning

confidence: 99%

Stimuli‐Responsive Delivery of Growth Factors for Tissue Engineering

Jiang

Zhou

et al. 2020

Adv Healthcare Materials

View full text Add to dashboard Cite

Growth factors (GFs) play a crucial role in directing stem cell behavior and transmitting information between different cell populations for tissue regeneration. However, their utility as therapeutics is limited by their short half‐life within the physiological microenvironment and significant side effects caused by off‐target effects or improper dosage. “Smart” materials that can not only sustain therapeutic delivery over a treatment period but also facilitate on‐demand release upon activation are attracting significant interest in the field of GF delivery for tissue engineering. Three properties are essential in engineering these “smart” materials: 1) the cargo vehicle protects the encapsulated therapeutic; 2) release is targeted to the site of injury; 3) cargo release can be modulated by disease‐specific stimuli. The aim of this review is to summarize the current research on stimuli‐responsive materials as intelligent vehicles for controlled GF delivery; Five main subfields of tissue engineering are discussed: skin, bone and cartilage, muscle, blood vessel, and nerve. Challenges in achieving such “smart” materials and perspectives on future applications of stimuli‐responsive GF delivery for tissue regeneration are also discussed.

show abstract

Section: Stimuli‐responsive Growth Factor Delivery Systems In Tissue mentioning

confidence: 99%

Stimuli‐Responsive Delivery of Growth Factors for Tissue Engineering

Jiang

Zhou

et al. 2020

Adv Healthcare Materials

View full text Add to dashboard Cite

show abstract

“…Skin grafts, including bioengineered or artificial skin, autografts, allografts, or xenografts from animal tissue, have produced promising results in clinical trials for diabetic foot ulceration (Santema et al, 2016). While many bioactive approaches have been explored to improve wound care in diabetic patients (Calderini et al, 2014), many of these have been found to be ineffective in clinical trials, and these non-healing wounds remain a major clinical challenge (Steed et al, 1992; Richard et al, 1995; Wieman et al, 1998; Steed, 2006; Uchi et al, 2009; Marti-Carvajal et al, 2015). …”

Section: Introductionmentioning

confidence: 99%

Biomaterials and Nanotherapeutics for Enhancing Skin Wound Healing

Baker

2016

Front. Bioeng. Biotechnol.

230

183

View full text Add to dashboard Cite

Wound healing is an intricate process that requires complex coordination between many cell types and an appropriate extracellular microenvironment. Chronic wounds often suffer from high protease activity, persistent infection, excess inflammation, and hypoxia. While there has been intense investigation to find new methods to improve cutaneous wound care, the management of chronic wounds, burns, and skin wound infection remain challenging clinical problems. Ideally, advanced wound dressings can provide enhanced healing and bridge the gaps in the healing processes that prevent chronic wounds from healing. These technologies have great potential for improving outcomes in patients with poorly healing wounds but face significant barriers in addressing the heterogeneity and clinical complexity of chronic or severe wounds. Active wound dressings aim to enhance the natural healing process and work to counter many aspects that plague poorly healing wounds, including excessive inflammation, ischemia, scarring, and wound infection. This review paper discusses recent advances in the development of biomaterials and nanoparticle therapeutics to enhance wound healing. In particular, this review focuses on the novel cutaneous wound treatments that have undergone significant preclinical development or are currently used in clinical practice.

show abstract

“…For example, recombinant human VEGF-A has not been approved for clinical use by the U.S. Food and Drug Administration (FDA) due to a negative result in phase II clinical trials 41 . PDGF-BB (Regranex in the clinic) has shown clinical efficacy, but safety issues such as cancer risk have been flagged, potentially due to high dosing 24,42 . Thus, controlling GF delivery to improved efficacy and dose reduction seems essential in future GF-based therapies and could be achieved by use of biomaterials 26 .…”

Section: Discussionmentioning

confidence: 99%

“…Later, some ECM proteins have raised interest for their ability to regulate the partitioning and bioavailability of soluble signaling molecules within tissues, thus highlighting a new role for the ECM in coordinating the spatio-temporal release of these molecules. Examples of such soluble signals are growth factors, which are key morphogenetic proteins broadly involved in the control of core cellular behaviors, and which have been shown to be crucial for wound healing [22][23][24] . Particularly, fibronectin 25,26 , vitronectin 27 , and fibrinogen 28 have been reported to directly bind to GFs, which control their release kinetics in vivo, acting as a GF reservoir.…”

Section: Introductionmentioning

confidence: 99%

Laminin heparin-binding peptides promiscuously bind growth factors and enhance diabetic wound healing

Ishihara

Fukunaga

Briquez

et al. 2018

Preprint

View full text Add to dashboard Cite

Laminin, as a key component of the basement membrane extracellular matrix (ECM), regulates tissue morphogenesis. We show that multiple laminin isoforms promiscuously bind to growth factors (GFs) with high affinity, through their heparin binding domains (HBDs) located in the a chain LG domains.Interestingly, these domains also bind to syndecan cell-surface receptors, promoting attachment of fibroblasts and endothelial cells. We next explore application of these multifunctional laminin HBDs in skin healing in the type 2 diabetic mouse. We demonstrate that covalent incorporation of laminin HBDs into fibrin matrix enables the slow-release of GFs. Incorporation of the α3

show abstract

Growth factors for treating diabetic foot ulcers

Cited by 109 publications

References 151 publications

Stimuli‐Responsive Delivery of Growth Factors for Tissue Engineering

Stimuli‐Responsive Delivery of Growth Factors for Tissue Engineering

Biomaterials and Nanotherapeutics for Enhancing Skin Wound Healing

Laminin heparin-binding peptides promiscuously bind growth factors and enhance diabetic wound healing

Contact Info

Product

Resources

About